Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Click to view the official SEC document.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Click to view the official SEC document.

Click to view the official SEC document.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Quanterix (QTRX) granted equity-based inducement awards on September 15, 2026 to new hires, including Chief Commercial Officer James Gute, under Nasdaq Listing Rule 5635(c)(4).Gute received an inducement grant of 260,315 restricted stock units (RSUs), representing the same number of common shares. Two other employees received a combined 365,326 RSUs, also representing 365,326 common shares. All RSUs vest in four equal annual installments on the first four anniversaries of the grant date, contingent on each recipient’s continued employment with Quanterix or its subsidiaries. The awards were issued under the Quanterix Amended and Restated 2025 Inducement Plan and were approved by the Board’s Compensation Committee as a material inducement to the employees’ commencement of employment.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

🚨BREAKING: The Department of Homeland Security (DHS) has published a new webpage that will help carry out President Donald Trump’s plans to create a national voter registry and shape who can vote in t...

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Several analysts have recently updated their ratings and price targets for Quanterix (NASDAQ: QTRX): 8/17/2026 – Quanterix had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $3.00. They now have a “hold” rating on the stock. 8/15/2026 – Quanterix was downgraded by Wall Street Zen from “hold” to “sell”. 8/11/2026 – [...]

YouTube video by Muted Vocal

Click to view the official SEC document.

YouTube video by x3NiiNax3

Click to view the official SEC document.

Click to view the official SEC document.

Quanterix (NASDAQ: QTRX) reported second quarter 2026 revenue of $32.9 million, up 34% year over year, with GAAP gross margin of 38.5% and non-GAAP gross margin of 47.9%. Adjusted EBITDA loss was $10.0 million, an improvement from a $13.7 million loss a year ago. The company ended the quarter with $96.9 million in cash, cash equivalents, marketable securities, and restricted cash, and adjusted cash usage was $4.0 million.Quanterix completed its ERP integration from the Akoya acquisition, achieving $85 million in annualized savings, but recorded a $26.9 million goodwill impairment related to Akoya. Leadership additions included a new Chief Commercial Officer, COO, CFO, and Diagnostics GM. In Alzheimer’s, Anthem Blue Cross and Blue Shield began covering qualifying blood-based biomarker tests, including Lucent AD® Complete, and new clinical data supported the company’s multi-analyte approach. Quanterix was also selected as a co-investigator in the PD-BUILD Parkinson’s biomarker program and launched new Simoa and spatial products.For 2026, Quanterix now expects revenue of $142–$148 million (down from $169–$174 million), non-GAAP gross margin of 48–50% (previously 49–53%), cash flow breakeven in 2027, and a year-end 2026 cash balance of about $80 million, with no debt.

Quanterix (Nasdaq: QTRX) has appointed experienced healthcare executive Jim Gute as Chief Commercial Officer, based at its Billerica, MA headquarters. He is charged with leading a re-acceleration of growth in commercial operations as the company prepares to expand its diagnostics business and strengthen its core offerings.According to Quanterix, Gute brings about 20 years of senior commercial leadership, including roles as President of GE Healthcare and Senior Vice President and Commercial Manager, General Screening, at Exact Sciences, a company with nearly $3 billion in revenue prior to its acquisition by Abbott Labs in early 2026.